ArticleJournal of general internal medicine2025
Clinical Outcomes in Acute Decompensated Metabolic Dysfunction-associated Steatotic Liver Disease Cirrhosis: The Role of BMI in Mortality, Readmission, and Hospital Stay.
Article in Journal of general internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical outcomes of lean metabolic dysfunction-associated steatotic liver disease by phenotypic subtypes.Journal of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study examines the impact of Body Mass Index (BMI) on mortality, readmission rates, and hospital stay lengths in patients with acute decompensated non-alcoholic fatty liver cirrhosis, now termed metabolic dysfunction-associated steatotic liver disease (MASLD).
objectiveTo assess the relationship between BMI and outcomes such as mortality, readmission rates, and hospital and ICU lengths of stay in patients with acute decompensated MASLD.
designRetrospective cohort analysis.
participantsConducted at Grand Strand Medical Center, Myrtle Beach, SC, this study included 43,942 patients, using data from the Hospital Corporation of America Enterprise Data Warehouse from 2017-2022. MAIN MEASURES: Logistic regression and negative binomial models were used, adjusting for age, gender, race, diabetes, and hyperlipidemia. KEY
resultsA notable "obesity paradox" was observed: underweight patients had over twice the odds of mortality (OR = 2.12, 95% CI: 1.83-2.46; p < 0.0001) compared to healthy-weight patients, suggesting a protective effect of higher BMI. While BMI did not significantly affect overall readmission, patients with Class III obesity had lower readmission odds (OR = 0.86, 95% CI: 0.77-0.96; p = 0.0012). However, Class III obesity was linked to increased hospital (IRR = 1.20, 95% CI: 1.15-1.26; p < 0.0001) and ICU LOS (IRR = 1.12, 95% CI: 1.04-1.20; p < 0.0001). Diabetes (IRR = 1.09, 95% CI: 1.06-1.11) and hyperlipidemia (IRR = 1.34, 95% CI: 1.31-1.38) were also associated with longer LOS (p < 0.0001).
conclusionThese findings highlight the complexity of BMI's role in MASLD outcomes. The observed obesity paradox warrants further investigation to inform care strategies across BMI categories.
Identifiers
40624325What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.